Total Revenue
United Therapeutics Total Revenue decreased by 1.1% to $781.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.6%, from $794.40M to $781.50M. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 17.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Detailed definition
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Peer comparison
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $446.50M | $444.70M | $415.20M | $461.90M | $466.90M | $516.00M | $491.50M | $506.90M | $596.50M | $609.40M | $614.70M | $677.70M | $714.90M | $748.90M | $735.90M | $794.40M | $798.60M | $799.50M | $790.20M | $781.50M |
| QoQ Change | — | -0.4% | -6.6% | +11.2% | +1.1% | +10.5% | -4.7% | +3.1% | +17.7% | +2.2% | +0.9% | +10.2% | +5.5% | +4.8% | -1.7% | +7.9% | +0.5% | +0.1% | -1.2% | -1.1% |
| YoY Change | — | — | — | — | +4.6% | +16.0% | +18.4% | +9.7% | +27.8% | +18.1% | +25.1% | +33.7% | +19.8% | +22.9% | +19.7% | +17.2% | +11.7% | +6.8% | +7.4% | -1.6% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Tyvaso DPI | $258.30M | $274.60M | $273.20M | $302.50M | $315.20M | $336.20M | $338.60M | $330.30M |
| Orenitram | $107.10M | $113.20M | $107.80M | $120.70M | $123.90M | $131.10M | $121.20M | $135.60M |
| Nebulized Tyvaso | $139.90M | $159.20M | $142.70M | $163.80M | $154.40M | $141.80M | $125.70M | $127.20M |
| Remodulin | $147.30M | $128.30M | $134.50M | $138.20M | $134.70M | $125.90M | $128.00M | $126.60M |
| Unituxin | $51.70M | $61.10M | $67.50M | $58.20M | $58.40M | $47.90M | $62.30M | $53.60M |
| Adcirca | $5.70M | $7.00M | $4.70M | $6.00M | $6.50M | $9.70M | $7.80M | $2.90M |
| Total | $714.90M | $748.90M | $735.90M | $794.40M | $798.60M | $799.50M | $790.20M | $781.50M |
Geographic Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| ROW | $39.70M | $31.60M | $30.20M | $44.80M | $38.80M | $24.70M | $37.40M | $37.30M |
| Total | $714.90M | $748.90M | $735.90M | $794.40M | $798.60M | $799.50M | $790.20M | $781.50M |
Total Revenue at Other Companies
Frequently Asked Questions
- What is United Therapeutics's total revenue?
- United Therapeutics (UTHR) reported total revenue of $781.50M in Q1 2026.
- How has United Therapeutics's total revenue changed year-over-year?
- United Therapeutics's total revenue decreased by 1.6% year-over-year, from $794.40M to $781.50M.
- What is the long-term trend for United Therapeutics's total revenue?
- Over 4 years (2021 to 2025), United Therapeutics's total revenue has grown at a 17.2% compound annual growth rate (CAGR), from $1.69B to $3.18B.
- What does total revenue mean?
- The total amount of money a company brings in from its primary business activities before any expenses.